Exelixis Inc. (EXEL) Gains Uptrend, Market Potential Reaches $1 Billion

Exelixis Inc., a pharmaceutical company focused on developing novel small molecule drug therapies for cancer treatment, is poised for significant growth. The company's lead drug candidate, XL184, has a 90% chance of reaching commercialization, according to FDA statistics. With a market potential of over $1 billion, Exelixis Inc. is attracting attention from big pharmaceutical companies, including Bristol-Myers Squibb, Sanofi-Aventis, and GlaxoSmithKline.

Key Takeaways:

Exelixis Inc. (EXEL) is engaged in the development of novel small molecule drug therapies for cancer treatment, with a focus on partnering with big pharmaceutical companies.
The company's lead drug candidate, XL184, has a 90% chance of reaching commercialization, with a market potential of over $1 billion.
Exelixis Inc. has partnered with multiple big pharmaceutical companies, including Bristol-Myers Squibb, Sanofi-Aventis, GlaxoSmithKline, and others.
The company's drug candidates, XL147 and XL765, have prospects of reaching commercialization at approximately 50% with successful phase II completion.
Pharmaceutical companies with revenue of over $1 billion include Cephalon Inc. (Nasdaq:CEPH) and King Pharmaceuticals (Nasdaq:KG).
Exelixis Inc. trades at a market capitalization of $673 million, compared to $4.27 billion for Cephalon Inc. and $2.62 billion for King Pharmaceuticals.

Statistics:

Market potential for Exelixis Inc.'s lead drug candidate, XL184: over $1 billion
Chance of XL184 reaching commercialization: 90% (according to FDA statistics)
Market capitalization of Exelixis Inc.: $673 million (as of September 8)
Market capitalization of Cephalon Inc.: $4.27 billion
Market capitalization of King Pharmaceuticals: $2.62 billion

Sources:

Beacon Equity (report announcement)
BeaconEquity.com (investment report and website)
SmarTrend (Comtex SmarTrend Alert)